These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 11518063)
1. Neurochemical studies with St. John's wort in vitro. Simmen U; Higelin J; Berger-Büter K; Schaffner W; Lundstrom K Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S137-42. PubMed ID: 11518063 [TBL] [Abstract][Full Text] [Related]
2. In vitro binding studies with two hypericum perforatum extracts--hyperforin, hypericin and biapigenin--on 5-HT6, 5-HT7, GABA(A)/benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters. Gobbi M; Moia M; Pirona L; Morizzoni P; Mennini T Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S45-8. PubMed ID: 11518075 [TBL] [Abstract][Full Text] [Related]
3. Extracts and constituents of Hypericum perforatum inhibit the binding of various ligands to recombinant receptors expressed with the Semliki Forest virus system. Simmen U; Burkard W; Berger K; Schaffner W; Lundstrom K J Recept Signal Transduct Res; 1999; 19(1-4):59-74. PubMed ID: 10071750 [TBL] [Abstract][Full Text] [Related]
4. Preserved pharmacological activity of hepatocytes-treated extracts of valerian and St. John's wort. Simmen U; Saladin C; Kaufmann P; Poddar M; Wallimann C; Schaffner W Planta Med; 2005 Jul; 71(7):592-8. PubMed ID: 16041642 [TBL] [Abstract][Full Text] [Related]
5. Mechanism of action of St John's wort in depression : what is known? Butterweck V CNS Drugs; 2003; 17(8):539-62. PubMed ID: 12775192 [TBL] [Abstract][Full Text] [Related]
6. In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs. Butterweck V; Nahrstedt A; Evans J; Hufeisen S; Rauser L; Savage J; Popadak B; Ernsberger P; Roth BL Psychopharmacology (Berl); 2002 Jul; 162(2):193-202. PubMed ID: 12110997 [TBL] [Abstract][Full Text] [Related]
8. Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex. Gobbi M; Valle FD; Ciapparelli C; Diomede L; Morazzoni P; Verotta L; Caccia S; Cervo L; Mennini T Naunyn Schmiedebergs Arch Pharmacol; 1999 Sep; 360(3):262-9. PubMed ID: 10543427 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the synaptosomal uptake inhibition of serotonin by St John's wort products. Schulte-Löbbert S; Holoubek G; Müller WE; Schubert-Zsilavecz M; Wurglics M J Pharm Pharmacol; 2004 Jun; 56(6):813-8. PubMed ID: 15231048 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. Obach RS J Pharmacol Exp Ther; 2000 Jul; 294(1):88-95. PubMed ID: 10871299 [TBL] [Abstract][Full Text] [Related]
11. St. John's wort extracts and some of their constituents potently inhibit ultimate carcinogen formation from benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1. Schwarz D; Kisselev P; Roots I Cancer Res; 2003 Nov; 63(22):8062-8. PubMed ID: 14633740 [TBL] [Abstract][Full Text] [Related]
12. Effects of oral administration of extracts of Hypericum perforatum (St John's wort) on brain serotonin transporter, serotonin uptake and behaviour in mice. Hirano K; Kato Y; Uchida S; Sugimoto Y; Yamada J; Umegaki K; Yamada S J Pharm Pharmacol; 2004 Dec; 56(12):1589-95. PubMed ID: 15563766 [TBL] [Abstract][Full Text] [Related]
13. Aqueous ethanolic extract of St. John's wort (Hypericum perforatum L.) induces growth inhibition and apoptosis in human malignant cells in vitro. Hostanska K; Reichling J; Bommer S; Weber M; Saller R Pharmazie; 2002 May; 57(5):323-31. PubMed ID: 12061257 [TBL] [Abstract][Full Text] [Related]
14. Current St John's wort research from mode of action to clinical efficacy. Müller WE Pharmacol Res; 2003 Feb; 47(2):101-9. PubMed ID: 12543057 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of pancreatic lipase by the constituents in St. John's Wort: In vitro and in silico investigations. Hou XD; Guan XQ; Cao YF; Weng ZM; Hu Q; Liu HB; Jia SN; Zang SZ; Zhou Q; Yang L; Ge GB; Hou J Int J Biol Macromol; 2020 Feb; 145():620-633. PubMed ID: 31883893 [TBL] [Abstract][Full Text] [Related]
16. St John's wort, hypericin, and imipramine: a comparative analysis of mRNA levels in brain areas involved in HPA axis control following short-term and long-term administration in normal and stressed rats. Butterweck V; Winterhoff H; Herkenham M Mol Psychiatry; 2001 Sep; 6(5):547-64. PubMed ID: 11526469 [TBL] [Abstract][Full Text] [Related]
17. Effects of Hypericum perforatum (St. John's wort) on passive avoidance in the rat: evaluation of potential neurochemical mechanisms underlying its antidepressant activity. Misane I; Ogren SO Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S89-97. PubMed ID: 11518084 [TBL] [Abstract][Full Text] [Related]
18. St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. Barnes J; Anderson LA; Phillipson JD J Pharm Pharmacol; 2001 May; 53(5):583-600. PubMed ID: 11370698 [TBL] [Abstract][Full Text] [Related]
19. Researching the antidepressant actions of Hypericum perforatum (St. John's wort) in animals and man. Franklin M; Cowen PJ Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S29-37. PubMed ID: 11518072 [TBL] [Abstract][Full Text] [Related]
20. Screen of receptor and uptake-site activity of hypericin component of St. John's wort reveals sigma receptor binding. Raffa RB Life Sci; 1998; 62(16):PL265-70. PubMed ID: 9585174 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]